Thrall J H, Gillen M T, Johnson M C, Corcoran R J, Wartofsky L
AJR Am J Roentgenol. 1978 Mar;130(3):517-22. doi: 10.2214/ajr.130.3.517.
A method for quantifying thyroid gland iodine content using a modified fluorescence scanning system is described. The technique does not require a computer. Two single channel analyzers and digital scalers are used to determine net counts from iodine k-alpha x-rays and system response in counts per milligram is calibrated from studies of known quantities of iodine placed in thyroid phantoms. Fluorescence quantification of thyroid gland iodine content was performed in 250 patients with a wide variety of thyroid disorders. Thirty euthyroid patients judged to have no evidence of thyroid disease averaged 10.1 +/- 3.9 mg glandular iodine. Results for several major diagnostic categories were: untreated Graves' disease, 28 patients, 24.4 +/- 9.9 mg; diffuse euthyroid goiter, 14 patients, 16.1 +/- 7.4 mg; primary hypothyroidism, seven patients, 0.5 mg; and nontoxic multinodular goiter, 28 patients, 7.3 +/- 4.1 mg. Follow-up studies on patients treated for Graves' disease both medically and with 131I generally revealed elevated iodine contents in persistently hyperthyroid patients, lower than normal average amounts in euthyroid patients, and only trace amounts in hypothyroid patients. Although the clinical role of fluorescence iodine quantification remains to be fully established, the technique provides information not otherwise available on an important parameter of thyroid status.
描述了一种使用改良荧光扫描系统定量甲状腺碘含量的方法。该技术不需要计算机。使用两个单通道分析仪和数字定标器来确定碘Kα X射线的净计数,并根据放置在甲状腺模型中的已知量碘的研究校准每毫克计数的系统响应。对250例患有各种甲状腺疾病的患者进行了甲状腺碘含量的荧光定量分析。30名被判定无甲状腺疾病证据的甲状腺功能正常患者的腺碘平均含量为10.1±3.9毫克。几个主要诊断类别的结果如下:未经治疗的格雷夫斯病,28例患者,24.4±9.9毫克;弥漫性甲状腺肿,14例患者,16.1±7.4毫克;原发性甲状腺功能减退,7例患者,0.5毫克;非毒性多结节性甲状腺肿,28例患者,7.3±4.1毫克。对接受格雷夫斯病药物治疗和131I治疗的患者进行的随访研究通常显示,持续甲状腺功能亢进的患者碘含量升高,甲状腺功能正常的患者平均含量低于正常,甲状腺功能减退的患者仅含微量碘。尽管荧光碘定量的临床作用仍有待充分确立,但该技术提供了关于甲状腺状态这一重要参数的其他方法无法获得的信息。